NORTHWELL HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1997-01-01

Employees: -

Market Cap: -

Website: https://www.northwell.edu/

Clinical Trials

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Phase 1

Recruiting

Conditions: Brain Cancer
Brain Tumor
Brain Neoplasm, Malignant
Glioblastoma
Brain Neoplasm
EGFR Gene Overexpression
GBM

Interventions: Drug: Intra-arterial Cetuximab
Drug: Intra-arterial Mannitol

First Posted Date: 2016-08-10

Last Posted Date: 2024-01-24

Lead Sponsor: Northwell Health

Target Recruit Count: 33

Registration Number: NCT02861898

Locations: 🇺🇸
Lenox Hill Brain Tumor Center, New York, New York, United States

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Completed

Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Interstitial Lung Disease

First Posted Date: 2016-08-08

Last Posted Date: 2018-01-09

Lead Sponsor: Northwell Health

Target Recruit Count: 99

Registration Number: NCT02858791

Locations: 🇺🇸
Northwell Health, New Hyde Park, New York, United States

Music Therapy During Pediatric Extubation Readiness Trials

Not Applicable

Completed

Conditions: Respiratory Insufficiency

Interventions: Behavioral: Music Therapy

First Posted Date: 2016-07-27

Last Posted Date: 2023-09-13

Lead Sponsor: Northwell Health

Target Recruit Count: 17

Registration Number: NCT02845947

Locations: 🇺🇸
Cohen Children's Medical Center, New Hyde Park, New York, United States

Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain

Not Applicable

Conditions: Lupus Erythematosus, Systemic
Musculoskeletal Pain

Interventions: Device: Vagus nerve stimulation
Device: Sham vagus nerve stimulation

First Posted Date: 2016-07-06

Last Posted Date: 2020-09-09

Lead Sponsor: Northwell Health

Target Recruit Count: 18

Registration Number: NCT02822989

Locations: 🇺🇸
Feinstein Institute, Manhasset, New York, United States

Striatal Connectivity and Clinical Outcome in Psychosis

Completed

Conditions: Psychotic Disorders

Interventions: Drug: Risperidone or Aripiprazole (patients only)

First Posted Date: 2016-07-04

Last Posted Date: 2024-02-21

Lead Sponsor: Northwell Health

Target Recruit Count: 196

Registration Number: NCT02822092

Locations: 🇺🇸
Zucker Hillside Hospital, Glen Oaks, New York, United States

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Phase 2

Recruiting

Conditions: Brain Tumor
Anaplastic Oligoastrocytoma
Glioblastoma
Glioma
Brain Cancer
Brain Tumor, Recurrent
Anaplastic Astrocytoma
Brain Neoplasm
Brain Neoplasm, Malignant

Interventions: Drug: Intra-arterial Cetuximab
Drug: Intra-arterial Mannitol
Radiation: Hypofractionated re-irradiation

First Posted Date: 2016-06-15

Last Posted Date: 2023-11-08

Lead Sponsor: Northwell Health

Target Recruit Count: 37

Registration Number: NCT02800486

Locations: 🇺🇸
Lenox Hill Brain Tumor Center, New York, New York, United States

DBS for Obsessive-Compulsive Disorder

Not Applicable

Recruiting

Conditions: Obsessive-Compulsive Disorder (OCD)

Interventions: Device: Reclaim™ DBS Therapy

First Posted Date: 2016-05-16

Last Posted Date: 2024-07-16

Lead Sponsor: Northwell Health

Target Recruit Count: 50

Registration Number: NCT02773082

Locations: 🇺🇸
Zucker Hillside Hospital, Queens, New York, United States

The Use of Videoconferencing for Monitoring of Patients Post Urologic Surgery

Not Applicable

Completed

Conditions: Urology

Interventions: Other: Tele-rounding in post operative care

First Posted Date: 2016-05-13

Last Posted Date: 2019-08-08

Lead Sponsor: Northwell Health

Target Recruit Count: 107

Registration Number: NCT02771431

Locations: 🇺🇸
North Shore LIJ, New Hyde Park, New York, United States

Midodrine During Recovery From Septic Shock

Phase 4

Withdrawn

Conditions: Hypotension
Sepsis
Shock, Septic

Interventions: Drug: placebo
Drug: Midodrine

First Posted Date: 2016-05-12

Last Posted Date: 2017-11-06

Lead Sponsor: Northwell Health

Registration Number: NCT02771158

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Phase 4

Withdrawn

Conditions: SGLT-2 Inhibitors
Advanced Glycation End Products
Diabetes

Interventions: Drug: empagliflozin
Drug: linagliptin

First Posted Date: 2016-05-11

Last Posted Date: 2018-02-15

Lead Sponsor: Northwell Health

Registration Number: NCT02768220

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy